Usuki, Kensuke http://orcid.org/0000-0002-1216-4470
Ikezoe, Takayuki
Ishiyama, Ken
Kanda, Yoshinobu
Gotoh, Akihiko
Hayashi, Hideo
Shimono, Akihiko
Kitajima, Akiyo
Obara, Naoshi
Nishimura, Jun-ichi
Funding for this research was provided by:
Alexion Pharma G.K.
Article History
Received: 9 March 2023
Revised: 6 June 2023
Accepted: 12 June 2023
First Online: 21 July 2023
Declarations
:
: KU has received grants from Astellas Amgen Biopharma, Apellis, Takeda Pharmaceutical, Novartis Pharma, AbbVie, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, MSD, Astellas, Alexion Pharma, Kyowa Kirin, Gilead, Pfizer, Incyte, SymBio, Celgene, Sumitomo-Dainippon, Mundi, Yakult, Eisai, Otsuka Pharmaceutical, and Nippon Shinyaku; consulting fees from Alexion Pharma, Nippon Shinyaku, Chugai Pharmaceutical, Takeda Pharmaceutical, SymBio, Otsuka, Sanofi, Kyowa Kirin, Astellas, Sobi, and Alnylam Japan; and honoraria from Novartis Pharma, Alexion Pharma, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Celgene, Daiichi Sankyo, Takeda Pharmaceutical, Nippon Shinyaku, PharmaEssentia, Bristol-Myers Squibb, Yakult, Sanofi, Pfizer, AbbVie, Chugai Pharmaceutical, Astellas, Eisai, and MSD. TI has received consulting fees from Alexion Pharma and Chugai Pharmaceutical, and honoraria from Alexion Pharma. KI has received grants from Novartis Pharma. YK declared no conflicts of interest. AG has received grants from Eisai, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Nippon Shinyaku, Chugai Pharmaceutical, MSD, Otsuka Pharmaceutical, Sumitomo Pharma, Bayer Yakuhin, Daiichi Sankyo, and Nihon Pharmaceutical; and honoraria from Novartis Pharma, Alexion Pharmaceuticals, Eisai, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Nippon Shinyaku, Chugai Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, Daiichi Sankyo, Nihon Pharmaceutical, Kyowa Kirin, Janssen, Pfizer Japan, and Sanofi; and has served on advisory boards for PharmaEssentia Japan and Chugai Pharmaceutical. HH, AS, and AK are employees of and hold stock or stock options in Alexion Pharma. NO has received grants from Kyowa Kirin and honoraria from Novartis Pharma and Kyowa Kirin. JN received support from Alexion Pharma in relation to this manuscript; consulting fees from Alexion Pharma, Sanofi, Sobi, Roche, Chugai Pharmaceutical, Novartis Pharma, and Biocryst; is a coauthor on a patent application by Chugai Pharmaceutical; has served on advisory boards for Alexion Pharma, Sanofi, Sobi, Roche, Chugai Pharmaceutical, Novartis Pharma, and Biocryst; and has leadership roles for the AAMDS Foundation and Japan PNH Study Group.